Daclatasvir is a revolutionary medicine reaching new heights of success in the treatment of chronic diseases such as the hepatitis C virus (HCV). It belongs to a new class of direct-acting antiviral agents (DAAs) and inhibits the non-structural protein 5A (NS5A) enzyme, which is responsible for the replication, maturation, and packaging of the HCV’s genome. The introduction of Daclatasvir 60mg tablet has changed the landscape of hepatitis C treatment, providing an effective and efficient form of therapy. Targeting specific genotypes Daclatasvir 60MG tablet has the potential to cure chronic HCV specifically genotypes 1, 2, 3, and 4. Several clinical trials were conducted to evaluate the safety, effectiveness, and tolerability of the medicine. The results from both randomized and open-label studies were found to be significant, as the sustained virologic response was noted to be over 90%. Furthermore, the side effects observed were primarily limited to mild fatigue or gastrointestinal